Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

158.89
-2.1700-1.35%
Volume:71.19K
Turnover:11.38M
Market Cap:6.40B
PE:-58.03
High:161.75
Open:161.06
Low:158.42
Close:161.06
52wk High:200.00
52wk Low:62.18
Shares:40.27M
Float Shares:19.38M
Volume Ratio:0.74
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7382
EPS(LYR):-2.3141
ROE:-22.10%
ROA:-15.65%
PB:8.24
PE(LYR):-68.66

Loading ...

Belite Bio to Present Phase 3 Dragon Tinlarebant Results in Stargardt Disease at SOG Congress

Reuters
·
Aug 21

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

GlobeNewswire
·
Aug 21

Belite Bio price target raised to $206 from $201 at Morgan Stanley

TIPRANKS
·
Aug 16

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)

TIPRANKS
·
Aug 16

Belite Bio is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Aug 14

Mizuho Securities Remains a Buy on Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Aug 14

Belite Bio CEO Lin Yu-Hsin Disposes of 365 Shares Worth $65,061.11

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 Net Loss Widens

Reuters
·
Aug 14

Belite Bio, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

Belite Bio Q2 Non-GAAP Net Loss Widens

MT Newswires Live
·
Aug 13

Belite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) Estimate

Benzinga Earnings
·
Aug 13

Belite Bio Q2 Net Income USD -28.412 Million

Reuters
·
Aug 13

Belite Bio Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 13

Belite Bio Q2 Income from Operations USD -34.907 Million

THOMSON REUTERS
·
Aug 13

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Aug 13

Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease

Simply Wall St.
·
Aug 13

Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Aug 12

Belite Bio Price Target Raised to $214.00/Share from $200.00 by HC Wainwright & Co.

Dow Jones
·
Aug 12

Belite Bio, Inc : H.c. Wainwright Raises Target Price to $214 from $200

THOMSON REUTERS
·
Aug 12